Antiglucocoticoid treatments for depression
by
Young AH.
Aust N Z J Psychiatry. 2006 May;40(5):402-5.

ABSTRACT

Objective: To selectively review the literature germane to antiglucocoticoid treatments for depression. Method: Selective review of the relevant literature. Results: Dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis has been well-described in both bipolar and unipolar depression. Hypercortisolaemia, possibly secondary to breakdown in glucocorticoid-receptor-mediated negative feedback mechanisms within the HPA axis, may be central to the pathogenesis of both depressive symptoms and the neurocognitive deficits which characterize these disorders. Strategies to counteract the effects of elevated cortisol, which may potentially restore HPA axis integrity, have been the focus of recent research. Conclusions: Both preclinical and clinical studies report encouraging results which suggest that lowering circulating cortisol levels or blocking the effects of elevated cortisol with antagonists, which may up-regulate glucocorticoid receptors, has therapeutic benefits in terms of improvements in depressive symptoms and some domains of neurocognitive function.

Stress
Metyrapone
Ketoconazole
Cortisol blues
Antidepressants
Atypical depression
Retarded depression
New antidepressants
Stressed tree shrews
An individualised approach
Antidepressants: how fast?
Antidepressants: adverse effects
The monoamine theory of depression
Melancholic depression, hypercortisolism and CRH
Stress, dynorphin, dysphoria and the kappa opioid system

Refs
HOME
HedWeb
Future Opioids
BLTC Research
General Anaesthesia
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family